We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The firm had failed to adequately evaluate the impact of changes in production steps and equipment on the current validated state of critical intermediates and Active Pharmaceutical Ingredients.